Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)‘s stock had its “neutral” rating restated by Wedbush in a note issued to investors on Friday. They currently have a $13.00 target price on the stock. Wedbush’s price objective indicates a potential downside of 23.44% from the company’s current price.
Other analysts also recently issued reports about the stock. Cowen and Company set a $16.00 target price on shares of Ironwood Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, January 21st. Mizuho reaffirmed a “buy” rating and issued a $21.00 price target on shares of Ironwood Pharmaceuticals in a research note on Thursday. Zacks Investment Research downgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, January 11th. Finally, J P Morgan Chase & Co set a $21.00 price target on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, February 2nd. One analyst has rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $16.09.
Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) traded down 0.77% on Friday, reaching $16.85. The company had a trading volume of 181,067 shares. The stock’s market capitalization is $2.46 billion. The company has a 50 day moving average price of $15.42 and a 200 day moving average price of $14.86. Ironwood Pharmaceuticals has a 52-week low of $8.18 and a 52-week high of $17.24.
This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/ironwood-pharmaceuticals-inc-irwd-earns-neutral-rating-from-wedbush-2/1208363.html
This news story was originally reported by Zolmax and is the property of of Zolmax. If you are reading this news story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this news story can be read at https://zolmax.com/investing/ironwood-pharmaceuticals-inc-irwd-earns-neutral-rating-from-wedbush-2/1208363.html.
In related news, Director Lawrence S. Olanoff sold 3,200 shares of the company’s stock in a transaction on Monday, December 5th. The shares were sold at an average price of $15.68, for a total value of $50,176.00. Following the completion of the sale, the director now directly owns 26,105 shares in the company, valued at $409,326.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Halley E. Gilbert sold 37,385 shares of the company’s stock in a transaction on Tuesday, February 14th. The stock was sold at an average price of $16.75, for a total transaction of $626,198.75. Following the completion of the sale, the insider now owns 37,385 shares of the company’s stock, valued at $626,198.75. The disclosure for this sale can be found here. Insiders sold 106,572 shares of company stock valued at $1,710,391 over the last quarter. 7.17% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of IRWD. Adage Capital Partners GP L.L.C. boosted its stake in shares of Ironwood Pharmaceuticals by 185.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 5,424,600 shares of the company’s stock worth $86,143,000 after buying an additional 3,524,600 shares in the last quarter. Rubric Capital Management LP acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth about $19,495,000. State Street Corp boosted its stake in shares of Ironwood Pharmaceuticals by 10.6% in the fourth quarter. State Street Corp now owns 3,791,359 shares of the company’s stock worth $57,972,000 after buying an additional 363,423 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth about $5,091,000. Finally, Vanguard Group Inc. boosted its stake in shares of Ironwood Pharmaceuticals by 3.1% in the second quarter. Vanguard Group Inc. now owns 9,379,525 shares of the company’s stock worth $122,637,000 after buying an additional 281,658 shares in the last quarter. Hedge funds and other institutional investors own 96.01% of the company’s stock.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.